This webinar will provide an in-depth look at the draft ICH M13B guideline titled “Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver” that was endorsed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Assembly in March 2025.
Similar Posts
Early Alert: TactiFlex Ablation Catheter Issue from Abbott
Abbott has issued new instructions on removing TactiFlex Ablation Catheter, Sensor Enabled from its packaging due to tip detachment issuesRationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas Maltophilia
Rationale for FDA’s Position on Ceftazidime Breakpoints against Stenotrophomonas MaltophiliaPulmonary-Allergy Drugs Advisory Committee Roster
This page contains the Pulmonary-Allergy Drugs Advisory Committee roster, which lists the current members and the current number of vacancies for the committee.FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease
FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial diseaseChemspec Chemicals Private Limited – 718403 – 12/23/2025
CGMP/Active Pharmaceutical Ingredient (API)/AdulteratedGlenmark Pharmaceuticals Limited – 708270 – 07/11/2025
CGMP/Finished Pharmaceuticals/Adulterated